Please select a video to purchase 2023 Gyn Oncology Updates 2023 Head and Neck Cancer Updates A Case Presentation in Metastatic Breast Cancer - Opportunities for Immunotherapy A Complicated Case of Gastric Cancer Acquired Inhibitors in Cancer: State-of-the Art Management Acute Lymphoblastic Leukemia: Latest Advances Acute Myeloid and Lymphoid Leukemias Acute Myeloid Leukemia ADC in Breast Cancer Management ADC in NSCLC: CEACAM5 and Teliso-V ADC in NSCLC: TROP2 and HER3 in NSCLC ADCs in Cancer Addressing Disparities in Access to Supportive Care During Cancer Treatment and Survivorship: An Integrative Approach Adjuvant / Neo-adjuvant Systemic Therapy Adjuvant and Neo-adjuvant Therapy for Lung Cancer Adjuvant and Neoadjuvant Novel Concepts and Strategies in NSCLC Adjuvant Immunotherapy Position Adjuvant Therapy in Breast Cancer: State of the Art Adjuvant/Neo-adjuvant Systemic Therapy Advance in Treatment of Acute Lymphocyctic Leukemia Advanced Breast Cancer: State of the Art Advanced Urothelial Cancer Advances in Car-T Cells and Other Cellular Based Therapies Advances in Car-T Cells Development for Cancer Therapy Advances in Esophageal and Gastric Cancer Advances in Gastrointestinal Malignancies Advances in Head and Neck Cancers Including Thyroid Malignancies Advances in HER2 Positive Metastatic Breast Cancer Advances in Immunotherapy Advances in Metastatic Breast Cancer Advances in Non-PD(L)1 Immunotherapies Advances in Oncology 2019: Breast Cancer Update Advances in Oncology: Breast Cancer Update 2018 Advances in Small Cell Lung Cancer and Mesothelioma Advances in Small Cell Lung Cancer and Mesothelioma/Thymic Malignancies Advances in Targeted Therapy in Lung Cancer Advances in the Treatment of CNS Malignancies Advances in the Treatment of Triple-Negative Metastatic Breast Cancer Advances in Value Based Care Advantages and Disadvantages of VSP in Current Residency Training Agnostic Tumor Drug Development ALK & ROS-1: First Line & Mechanism of Resistance ALK in Front Line Therapy: Second or Third Generation TKI Inhibitors. What Can Help Us to Choose the Best Therapeutic Agent? ALK Mutant NSCLC ALK-Altered Non-Squamous NSCLC: Options and Sequence ALK, ROS-1, RET and MET ALK, ROS1 & BRAF Mutations in NSCLC ALK, ROS1 & NTRK Mutations in NSCLC ALK, ROS1, and BRAF Positive Lung Cancer ALK: Choosing 1L & Mechanism of Resistance ALK: First Line and Mechanism Of Resistance AML and MDS: Beyond 7+3 AML and MDS: Current Status and Future Directions AML: Current Status and Future Directions AML: Where Are We Now and Where Are We Going? An Overview of the Cancer Workup:From Biopsy to Surgery Angiogenesis, mTor pathway, and other Therapeutics for Kidney Cancer Anti-HER2 Therapies in Breast Cancer: Adjuvant and Neodjuvant Antibody Drug Conjugated for Breast Cancer: Current Therapy and New Directions Antibody Drug Conjugates for HER2 Negative Breast Cancer: A Revolution in Chemotherapy for Breast Cancer Antibody Drug Conjugates: New Agents and Optimal Sequencing Anticoagulation in Oncology: What’s New? Anticoagulation in the Oncology Patient Applying New Endocrine and Targeted Agents to the Treatment of Hormone Receptor Positive, HER2 Negative Breast Cancer Approach to NSCLC With Targetable Mutations (EGFR, ALK and ROS-1) Approach to NSCLC Without Targetable Mutations Are The New Changes in Congress an Answer for Inequity in Terms of Access to Molecular Testing and New Cancer Agents? Artificial Intelligence and Modern Medical Practice: Do’s and Don’ts Artificial Intelligence in Oncology Care ASCO GI 2023 Updates ASCO Update on Sarcomas Attracting, Recruiting and Retaining the Oncology Pharmacy Talent B-Cell Lymphomas: Updates and Future Directions B-Cell NHL (Aggressive) - Relapsed (CAR T versus Bispecifics?) B-Cell NHL (Low-Grades) B-Cell NHL and Hodgkin’s Disease B-cell NHL: Highlights from ASCO/EHA Bayesian Designs in Clinical Trials Bench Lab Advances for Breast Cancer Best Approaches for First Line EGFR Mutant NSCLC Best Surgical Approaches for Stage III NSCLC Bi-Specific Inhibitor & ADC in Lung Cancer Biomarkers for Perioperative Immunotherapy? Biomarkers in NSCLC: Current Status and Future Directions Biosimilars as Front-Line Options for Cancer Care Biosimilars Implementation in the United States: Where Opportunities Remain Bispecific Antibodies in Cancer Care: Actual Reality and Future Projections Bladder / Urothelial Cancer Updates Bladder and Kidney Bladder Cancer Update Bladder Cancer Updates Bladder Cancer: Novel Insights and Recent Approvals Bone Health in Cancer Care Bone Marrow Transplant and CAR T Cell Therapy in Hematology Malignancies Brain Radiotherapy in SCLC: When? Brain Tumors Breast Cancer Breast Cancer Immunotherapy Breast Cancer Session Breast Cancer Update in HER2 Breast Cancers Breast Cancer Update in Hormone Sensitive Breast Cancer Breast Cancer Update in Triple Negative and HER2 Breast Cancers Breast Cancer Update in Triple Negative Breast Cancer Breast Targeted Therapy - HER2, CDK 4-6, PI3KCA Breast Targeted Therapy: HER2, CDK 4/6, PI3KCA Bring New & Innovative Glioblastoma Treatments to the Clinical Practice Bringing Personalized Medicine to Colorectal Cancers BTK inhibitors, BCL-2 Inhibitors and Novel Targets in Hematology Building the Case for HER-2 Inhibitors in NSCLC Burkitt Lymphoma Cancer and Thrombosis What is the Role of Direct Oral Anticoagulants? Cancer and Thrombosis: State-of-the-Art Management Cancer and Thrombosis: What is the Role of Direct Oral Anticoagulants? Cancer Care Disparities in Puerto Rico (Part 1) Cancer Disparity from Different Angles: How to Tackle It? Cancer Genetic Risk Factors: What’s New and What You Need to Know? Cancer Immunotherapy Cancer Screenings, Reducing Mortality Cancer Survivorship: A Long-Term Journey Cancer-related Bleeding and Thrombosis Cannabis and Cancer: Myths and Reality CAR T Cell Therapies in Lymphoid Malignancies: Here to Stay! CAR-T Cell as Strategy for the Management of Hematologic Malignancies CAR-T Cell in NSCLC: Is it Feasible? CAR-T Cell Therapy in Lymphomas: 7-Years Later CAR-T Cells and Other Cell Based Therapies CAR-T Cells: Learning How to Deal with Complications Case Presentation - Breast Case Presentation - GU Case Presentation - Lung - Immunotherapy Toxicity Case, How to Manage and Whether to Permanently Stop or Not Castration Resistant Prostate Cancer (CRPC), Non-Metastatic & Metastatic: Novel Therapeutic Advances Castration Resistant Prostate Cancer: What is the optimal approach? Castration Resistant Prostate Cancer: What is the Optimal Treatment? CDK4/6, PIK3CA & PARP Inhibitors in MBCA Challenges in Her-2 Breast Cancer Challenges in Immunotherapy in NSCLC Challenges in Lung Cancer Pathology: Biomarkers Challenges in Targeting Head and Neck Squamous Cell Carcinoma Challenging Case #2: Genitourinary Cancer Challenging Cases in Breast Cancer Challenging Cases in Oncology Changing Delivery of Chemotherapy for Breast Cancer: The Broad Impact of Antibody Drug Conjugates Chimeric Antigen Receptor (CAR) T-Cell Therapy: Progress and Challenges Chimeric Antigen Receptor T-Cell Therapy: Indications and Remaining Challenges Cholangiocarcinoma and Hepatocellular Cancer Cholangiocarcinoma/Hepatocellular & Pancreas Cancer Choosing Optimal Therapy for Relapsed Multiple Myeloma Patient Chronic Lymphocytic Leukemia Chronic Lymphocytic Leukemias Clinical Utility and Future indications of Liquid Biopsies in Lung Cancer CLL and CML CLL: At Recurrence- What is the Best Therapy and What is Coming from the Bench Lab? CLL: How Do You Decide the Best Frontline Therapy? CLL: Novel Therapies CLL: Therapeutic Advances in 2024 CNS Lymphomas Colon and Rectal Cancer: Novel Therapies and Future Approaches Colon Cancer Updates Colon Cancer: Are We Making Progress? Colon Cancer: Novel Therapies and Future Approaches Colon Cancer: State of the Art Colon Cancer: Where Are We? Colorectal and Anal Cancer Update Colorectal Cancer: Chemotherapy Combinations Targeted Therapy and Immunotherapy Colorectal Cancer: Novel Treatment Paradigms Colorectal Cancer: State of the Art Colorectal Cancer: State of the Science Colorectal Cancers: Where Are We Moving? Combination Radiation and Immunotherapy Contemporary Management of Urothelial Cancer Controversies in Breast Cancer: Use of ctDNA to Tailor Systemic Adjuvant / Post-neoadjuvant Therapies (Part 1) Controversies in Breast Cancer: Use of ctDNA to Tailor Systemic Adjuvant / Post-neoadjuvant Therapies (Part 2) Controversies in Colon Cancer- ctDNA in the Adjuvant Therapy of Colon Cancer and in the Management of Oligometastases (Against) Controversies in Colon Cancer- ctDNA in the Adjuvant Therapy of Colon Cancer and in the Management of Oligometastases (in Favor) Controversies in Lung Cancer:
Neoadjuvant vs Adjuvant IO in Early Stage NSCLC Controversy in Breast Cancer- Should be pCR Be an Acceptable Endpoint for Approval of New Therapies for Early-Stage Breast Cancer (NO) Controversy in Breast Cancer- Should be pCR Be an Acceptable Endpoint for Approval of New Therapies for Early-Stage Breast Cancer (YES) Convergence of Liquid Biopsy and Precision Oncology in the Management of NSCLC Cost and Access to Novel Therapeutic Agents? Where Are The Obstacles? Cost of Medications: How to Make Them Affordable—Are We on the Right Direction? CRC Updates CTCL: Micosis Fungoides & Sezary Syndrome ctDNA in Adjuvant and Metastatic Therapy for GI Cancers: Prime Time? ctDNA in Lung Cancer: Current State and Future Perspectives Current Issues in Checkpoint Immunotherapy for NSCLC: A Perspective from February 2020 Current Standard of Therapies in CLL Current State of Lung Cancer Screening Current Status of CAR-T Therapy in Hematology Current Status of Cervical Cancer Screening Cutaneous Melanoma, New Developments for 2018 and Beyond DDR and DNA-Repair Pathways and Targets De Novo Acute Myeloid Leukemia Dealing with EGFRex19del & L858R, ALK, and KRASg12c Genetic Aberrations Delayed Replantation of an Avulsed Maxillary Lateral Incisor: A Case Report Developing New Anti-CTL4s for NSCLC: Is There Any Role? Developing Targeted therapy for GU malignancies Developmental Therapeutics and Novel Agents Developments in Gastric, and Esophageal Tumors Developments in Head and Neck Cancers Including Thyroid Malignancies Diabetes Management in the Face of Healthcare Disparities Diagnosis and Management of Dentin Hypersensitivity Disparities in Breast Cancer Therapy Outcomes DLBCL & Hodgkin’s Disease DLBCL & Hodgkin’s Disease: Novel Approaches DLBCL: Current Therapeutic Approaches DLBCL: The Latest and Greatest Double Hit Lymphomas Drug Brown and White Bagging - What is It and Where Does it Lead Us? Drug Brown and White Bagging: What is It and Where Does it Lead Us? Drug Development and New Targeted Agents for Breast Cancer: What Does the Future Hold? Early Stage TNBC: Reviewing Different Strategies and Management Early-Stage / Locally Advanced Lung Cancer Early-Stage Colon Cancer Early-Stage/Locally Advanced Lung Cancer EGFR & ALK: Where Are We Now? EGFR and K-RAS Mutations in NSCLC EGFR and Resistant Mechanisms EGFR Exon 20 Insertions: Novel Agents EGFR Mutated Lung Cancer - Advanced Stage EGFR Mutations: What's Next? EGFR PKI Resistance and K-RAS Mutations EGFR-Mutated Lung Cancers EGFR, K-RAS and ERBB2 Mutations in NSCLC EGFR: Common and Uncommon Mutations and What Is Next for This Patient Population EGFRex20ins, METex14 and RET in NSCLC Eliminate the Barriers for Disparity in Cancer Care in the 21st Century Emerging Combination in Sarcoma Immunotherapy Emerging Systematic Treatments for Head and Neck Cancers End of Life Management: Oncologists’ Perspectives Endocrine Therapy and Targeted Agents for Early-Stage HR+ Breast Cancer Endocrine Therapy for Advanced Breast Cancer: Current and Future Strategies Endocrine Therapy for Early -and Late- Stages Breast Cancer: Therapeutic Updates Endocrine Therapy for Early-Stage Breast Cancer: Who Needs more? Endocrine Therapy in Non-Metastatic Breast Cancer Setting Endocrine Therapy in the Neoadjuvant & Adjuvant Setting Equity and Equality for Minorities in Cancer Care Equity in Cancer Care: Efforts Tackling Barriers at the Government and Legislation Levels ER/PR and CDK Pathways in the Management of ER+ Metastatic Breast Cancer ER/PR Breast Disease: Early Stage- Locally Advanced and Metastatic Breast Cancer ER/PR Breast Disease: Early Stage, Locally Advanced and Metastatic Breast Cancer ERBB2 and NGR1 Pathways in NSCLC Esophageal and Gastric Cancer: New Developments Esophageal, Gastric and GE Junction Tumors: What’s New in 2023? Esophagus and Gastric Cancer Update Establishing IO Management in Gastrointestinal Cancers Exon 20 and Uncommon EGFR Sensitive Mutations Favoring The Adjuvant Concept Favoring The Neoadjuvant Concept Follicular Lymphoma: Defining Best 1L and 2L Treatment in the Era of Personalized Medicine Follicular Lymphoma: Novel Advances and Pathways Follicular, Marginal Zone and Mantle Cell NHL: Novel Advances From Bench to Bedside (and Back): Early Clinical Trials From the Young to the Grown-up; Pharmacotherapy Updates in Acute Lymphoblastic Leukemia (ALL) Front Line Targeted Therapy in NSCLC: Tyrosine Kinase Inhibitors Frontline: What are We Adding to Checkpoint Inhibitors and Chemotherapy? Future Challenges for Immunotherapy in the Fight Against NSCLC Gastric and Esophageal Cancer Updates Gastric and Esophageal Cancers Gastric, Esophagael, and Circulating Tumor Cells in GI Cancers Gastrointestinal Cancer Gastrointestinal Malignancies Session GBM, Oligodendriogliomas and Malignant Schwanomas: Novel Therapies Gene Therapies and Immunotherapy Updates in Solid Tumor Malignancies Genitourinary and Gynecologic Malignancies Session Genitourinary Cancer Genomics and Cancer Disparities Geriatric Oncology: Pitfalls to Deliver Good Care in the Elderly Cancer Patient GIST and Soft Tissue Sarcomas: Focus on Personalized Medicine Global Health and ASCO Update GU Cancer and State of the Art: Castration Resistant Prostate Cancer GU Liquid Biopsy Updates Guidelines for Hormone Therapy in Breast Cancer Gynecologic Cancer Gynecologic Malignancies: New Targeted Therapy-IO-Chemo Combinations Gynecologic Malignancies: Targeted Therapy-IO-Chemo Combinations Handling Common Toxicities of Immune Checkpoint Inhibitors Head & Neck Cancers, Brain Tumors and Sarcoma Session Head and Neck Cancer Head and Neck Cancers Health Care Disparities in Lung Cancer Genomic Profiling Health, Wellness and Cancer Prevention Hematologic Malignancies Hematology Malignancies Session Hematology Session I Hematology Session II Hematology Session III Hepatocellular and Biliary Cancers: Recent advances Hepatocellular Cancer and Cholangiocarcinoma Updates Hepatocellular Cancer: Latest Advances HER-2 Disease: Amplification/Overexpression/Mutation in Breast Cancer HER-3 as a New Target in NSCLC HER+, ER+, San Antonio Update HER2 Breast Cancer HER2 Targeted Therapies: Recent Advances HER2-Driven Breast Cancer: Current Status and Next Generation Therapeutics HER2-Positive Breast Cancer Updates HER2+ Breast Cancer: De-escalating Therapy for Early Stage Disease and Optimal Sequencing for Metastatic Disease HER2+ Breast Cancer: State of the Art Hormone Receptor Breast Cancer Hormone Sensitive Metastatic Prostate Cancer Hormone Therapy in Breast Cancer: New Directions How Far Have We Gone with Biosimilars? How I Treat Acute Myeloid Leukemia How I Treat Advanced Head and Neck Cancer How I Treat AML in 2023 How I Treat Locally Advanced Head and Neck Cancer How I Treat Metastatic Bladder Cancer in 2023 How I Treat Metastatic Colorectal Cancer in 2023 How I Treat Metastatic Esophageal and Gastric Cancer in 2023 How I Treat Metastatic HER2+/HER2-Low Breast Cancer in 2023 How I Treat Metastatic Prostate Cancer in 2023 How I Treat Metastatic Renal Cell Cancer in 2023 How I Treat Metastatic Urothelial Cancer after IO Therapy Fails How I Treat Multiple Myeloma How I Treat Multiple Myeloma in 2023 How I treat Stage III NSCLC How I Treat Triple Negative Breast Cancer in 2023 How To Approach A Newly Diagnosed Myeloma Patient? How to Choose Front Line Therapy for Metastatic Non-Driver Mutation NSCLC How to Choose the Best 1L in a Newly Diagnosed Multiple Myeloma Patient? How to Combine RT and Immunotherapy Without Compromising Anti-tumor Effect? How to Handle Myelotoxicity from Chemotherapy in 2024: From Colony-Stimulating Factors (CSF) to Agents
Providing Myeloprotection to the Three Cell Lines How to Handle the Onco-Geriatric Patient: Facts and Myth How to Improve Targeted Therapy in NSCLC? Where are the Major Gaps? How to Navigate Through Relapsed-Refractory Myeloma Patient How to Rescue Patients from Osimertinib Resistance How to Start a Lung Cancer Screening Program HRPC: How to Sequence Multiple Therapies Identifying and Targeting Mechanisms of Resistance to 3rd Generation EGFR Inhibitors Immunotherapies in Gynecologic Malignancies Immunotherapy Immunotherapy & Targeted Therapy in Colon Cancer Immunotherapy & Targeted Therapy in Melanoma Immunotherapy and Other Systemic Therapy in Gynecologic Malignancies Immunotherapy and Side Effect Management: Challenging Cases Immunotherapy and Targeted Therapy in Melanoma Immunotherapy for Advanced Non-Small Cell Lung Cancer Immunotherapy for Advanced NSCLC Immunotherapy for Breast Cancer: Current and Future Directions Immunotherapy for Breast Cancer: Efficacy and Toxicity Considerations Immunotherapy for Breast Cancer: Updates and New Directions Immunotherapy for Early-Stage Lung Cancer: Adjuvant and Neoadjuvant Approaches Immunotherapy for GU Malignancies and Exciting Developments Immunotherapy for GYO Malignancies: Is There Still Time for Progress? Immunotherapy for Head and Neck Cancers Immunotherapy for Melanoma Immunotherapy for Triple Negative Breast Cancer Immunotherapy in Advanced NSCLC: Initial Therapy and How to Overcome Resistance Immunotherapy in Advanced/ Metastatic NSCLC Immunotherapy in Advanced/Metastatic NSCLC and What After IO Failures? Immunotherapy in Breast Immunotherapy in Breast Cancer Immunotherapy in Breast Cancer: Now & The Future Immunotherapy in Breast Cancer: Recent Updates Immunotherapy in Cancer: Next Generation Biomarkers Immunotherapy in Colorectal Cancer & MSI-High Solid Cancers Immunotherapy in Gynecologic Malignancies Immunotherapy in Head & Neck Cancer Immunotherapy in Head & Neck Cancer and What After IO Failure? Immunotherapy in Head and Neck Cancer Immunotherapy in Kidney & Bladder Immunotherapy in Kidney & Bladder Cancer Immunotherapy in Kidney & Bladder Cancers Immunotherapy in Kidney & Bladder Tumors Immunotherapy in Kidney and Bladder Cancers Immunotherapy in Lung Immunotherapy in Lung Cancer Immunotherapy in Lung Cancer: NEOADJ, ADJ and LA Disease Immunotherapy in Metastatic Breast Cancer Immunotherapy in Metastatic NSCLC: Frontline and What’s After Immunotherapy Failure Immunotherapy in Non-Melanoma Skin Cancers (BCC, Squamous & Merkel) and What After IO Failure? Immunotherapy in NSCLC: First Line for Advanced Disease Immunotherapy in Oncology Session I Immunotherapy in Oncology Session II Immunotherapy of Kidney and Bladder Cancer Immunotherapy selection in mRCC Immunotherapy Session Immunotherapy Toxicities and Lung Biomarkers Immunotherapy, Targeted Therapy & And What After in Melanoma? Impact of COVID-19 on Cancer Care Incorporating Immunotherapy and Novel Biological Agents in Breast Cancer: New Horizons Initiatives to Improve Equity and Inclusion in Healthcare Innovative Early Phase Clinical Trial Designs Integrating Biomarkers and Targeted Therapy into Colorectal Management Integrating Biomarkers into Targeted Therapy and Immunotherapy Clinical Trials Integration of Biosimilars in Oncology Care Integrative Oncology in Cancer Care Integrative Oncology: Treatment Approaches for Stress in Cancer Patients and Survivors Integrative Survivorship in Cancer Care ISLB and MCM Symposia K-RAS and ERBB2 Mutation in NSCLC K-RAS Therapies in NSCLC Keynote Lecture – The Future of Targeted Therapy in Lung Cancer Keynote Lecture: CAR-T Cell and Cellular Therapy Update Kidney & Bladder Cancer: Targeted, Immuno & Other Strategies Kidney Cancer: Novel Development in Targeted and Immunotherapy KRAS mutant NSCLC: What is the Standard of Care Now? KRAS: Deciphering the Mechanism of Resistance To First Generation KRAS Inhibitors Lack of Access to Novel Cancer Therapies: How to Deal and Approach this Problem? Diversity, Equity, & Inclusion Lack of Equity in Clinical Outcomes in African American and Hispanics with NSCLC Late Recurrences in ER Positive Breast Cancer: The Next Frontier? Later lines of Treatment for NSCLC Latest Treatments in Triple Negative Breast Cancer Launching a Busulfan Kinetics Pharmacy Service; Real-World Case in Community Hospital Setting Learning from BTK Inhibitors & Moving Forward the Therapeutic Field in CLL Leveraging NCODA Resources to Manage Patients on Oral Oncolytics Lifestyle Modifications in Reducing Risk of Recurrence Liquid Biopsies in Breast Cancer: Fact, Fiction, and Promise Liquid Biopsy Liquid Biopsy: Advances in the Last Decade and Future Directions Liquid Biopsy: How Are We Utilizing It and Where Is This Technology Moving To? Liquid Biopsy: Indications in Oncology and Hematology Liver and Hepatic Malignancies: Times to Overcome Challenges Locally Advanced Non-Small Cell Lung Cancer Locally Advanced NSCLC (Neoadjuvant/Adjuvant Therapies) Locally Advanced NSCLC Chemotherapy / Targeted Therapy / Immunotherapy Locally Advanced NSCLC- Radiation Therapy Locally Advanced SqCCHN: Best Frontline for Unresectable Cancer and What Is Next at Relapse? Lung Adenocarcinoma Updates Lung Cancer Lung Cancer Case Lung Cancer Clinical Scenarios: How Liquid Biopsy Technology Is Delivering Personalized Therapy in NSCLC Lung Cancer Immunotheraphy Case Presentation Lung Cancer Neoadjuvant and Adjuvant Immunotherapy Lung Cancer Screening / Tobacco Control Lung Cancer Session Lung Cancer With EGFR Exon 19 and L858R Mutations: The Optimal Front Line Therapy Lung Immunotherapy Lung Targeted Therapies in NSCLC - BRAF, RET, MET and NTRK Lung Targeted Therapies in NSCLC - EGFR, ALK, and ROS1 Lung Targeted Therapies IN NSCLC: EGFR, ALK, and ROS1 Lung Targeted Therapies in NSCLC: RET, MET and EGFR/HER-2 exon 20 Lymphoma and CLL Update Lymphoma: State of the Art Major Challenges Treating Myelodysplastic Syndrome Malignant Hematology and Use of Bi-specifics in Puerto Rico Management of EGFR Mutant NSCLC Patients and Future Directions (excluding Resistance to EGFR TKIs) Management of Immune Related Adverse Events